The global hepatitis therapeutics market is projected to reach US$ 21.9 Bn by 2031, driven by increasing incidence of hepatitis B and C, advancements in treatment modalities, and rising awareness. North America is leading the market due to a high prevalence of the disease and robust healthcare infrastructure.